Fight CRC Clinical Trial Finder

Date Trial Added
View:
NCT ID Title Phase Date Added Location Prior IO Allowed CRC-directed Status Drugs Tags
NCT ID
NCT04111172
TitleA Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma Phase
Phase 2
Date Added
2019-10-01
Location
Pennsylvania, United States
Prior IO Allowed
Yes
CRC-directed
Yes
Status
Active, not recruiting
Drugs
Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE
Tags
MSI-H/ MMRd, MSS/ MMRp
NCT ID
NCT03566355
TitleCurative Proton Beam Therapy for Patients With Lung Metastasis of Colorectal Cancer Phase
Not Applicable
Date Added
2018-06-25
Location
Korea, Republic of
Prior IO Allowed
Yes
CRC-directed
Yes
Status
Recruiting
Drugs
Tags
MSI-H/ MMRd, MSS/ MMRp
NCT ID
NCT04185883
TitleSotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) Phase
Phase 1
Date Added
2019-12-04
Location
Arizona, United States
California, United States
Colorado, United States
Connecticut, United States
Florida, United States
Georgia, United States
Illinois, United States
Indiana, United States
Iowa, United States
Maryland, United States
Michigan, United States
Missouri, United States
New York, United States
North Carolina, United States
Ohio, United States
Oregon, United States
Pennsylvania, United States
South Carolina, United States
South Dakota, United States
Tennessee, United States
Texas, United States
Utah, United States
Virginia, United States
Washington, United States
Australia
Austria
Belgium
Canada
Germany
Italy
Japan
Korea, Republic of
Netherlands
Spain
Taiwan
United Kingdom
Prior IO Allowed
Yes
CRC-directed
No
Status
Recruiting
Drugs
afatinib, AMG 404, Atezolizumab, carboplatin, pemetrexed, docetaxel, everolimus, FOLFIRI, FOLFOX, MVASI® (bevacizumab-awwb), palbociclib, panitumumab, Pembrolizumab, RMC-4630, Sotorasib, TNO155, Trametinib
Tags
MSI-H/ MMRd, MSS/ MMRp
NCT ID
NCT03740256
TitleBinary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors Phase
Phase 1
Date Added
2018-11-14
Location
Texas, United States
Prior IO Allowed
Yes
CRC-directed
Yes
Status
Recruiting
Drugs
CAdVEC
Tags
MSI-H/ MMRd, MSS/ MMRp
NCT ID
NCT02453620
TitleEntinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer Phase
Phase 1
Date Added
2015-05-25
Location
California, United States
Connecticut, United States
Maryland, United States
Pennsylvania, United States
Prior IO Allowed
Yes
CRC-directed
No
Status
Active, not recruiting
Drugs
Entinostat, Ipilimumab, Nivolumab, Opdivo, Yervoy
Tags
MSS/ MMRp
NCT ID
NCT03170960
TitleStudy of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase
Phase 1
Date Added
2017-05-31
Location
Arizona, United States
California, United States
Colorado, United States
Connecticut, United States
District of Columbia, United States
Florida, United States
Georgia, United States
Illinois, United States
Kansas, United States
Kentucky, United States
Louisiana, United States
Massachusetts, United States
Michigan, United States
Minnesota, United States
Missouri, United States
Nebraska, United States
Nevada, United States
New Jersey, United States
New York, United States
Ohio, United States
Oklahoma, United States
Oregon, United States
Pennsylvania, United States
South Carolina, United States
Texas, United States
Utah, United States
Virginia, United States
Australia
Belgium
France
Germany
Italy
Netherlands
Spain
United Kingdom
Prior IO Allowed
Yes
CRC-directed
Yes
Status
Active, not recruiting
Drugs
Atezolizumab, Cabozantinib
Tags
MSS/ MMRp
NCT ID
NCT03600883
TitleA Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100) Phase
Phase 1, Phase 2
Date Added
2018-07-26
Location
California, United States
Colorado, United States
Connecticut, United States
Delaware, United States
Florida, United States
Georgia, United States
Indiana, United States
Maryland, United States
Massachusetts, United States
Michigan, United States
Missouri, United States
New York, United States
North Carolina, United States
Ohio, United States
Pennsylvania, United States
South Carolina, United States
Tennessee, United States
Texas, United States
Utah, United States
Virginia, United States
Washington, United States
Australia
Austria
Belgium
Brazil
Canada
France
Germany
Greece
Hungary
Japan
Korea, Republic of
Portugal
Romania
Spain
Switzerland
Prior IO Allowed
Yes
CRC-directed
No
Status
Active, not recruiting
Drugs
Anti PD-1/L1, Midazolam, Sotorasib
Tags
MSS/ MMRp
NCT ID
PG545 (pixatimod) in combination with nivolumab
TitlePG545 (pixatimod) in combination with nivolumab Phase
Phase 1
Date Added
2019-04-26
Location
Prior IO Allowed
Yes
CRC-directed
Yes
Status
Recruiting
Drugs
Tags
MSI-H/ MMRd, MSS/ MMRp
NCT ID
NCT02668770
TitleIpilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies Phase
Phase 1
Date Added
2016-01-29
Location
Texas, United States
Prior IO Allowed
Yes
CRC-directed
No
Status
Active, not recruiting
Drugs
Ipilimumab, MGN1703
Tags
MSS/ MMRp
NCT ID
NCT02285816
TitleMG1 Maraba/MAGE-A3, With and Without Adenovirus Vaccine With Transgenic MAGE-A3 Insertion in Incurable MAGE-A3-Expressing Solid Tumours Phase
Phase 1, Phase 2
Date Added
2014-11-07
Location
Canada
Prior IO Allowed
Yes
CRC-directed
No
Status
Active, not recruiting
Drugs
AdMA3, MG1MA3
Tags
MSS/ MMRp